Lucid Diagnostics (NASDAQ:LUCD) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research report released on Thursday,Benzinga reports. Needham & Company LLC currently has a $3.00 price target on the stock.

Other equities research analysts also recently issued research reports about the company. Ascendiant Capital Markets increased their price objective on Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Monday, December 29th. Finally, Wall Street Zen lowered Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $3.94.

Lucid Diagnostics Trading Down 3.4%

Lucid Diagnostics stock opened at $1.15 on Thursday. Lucid Diagnostics has a 1-year low of $0.95 and a 1-year high of $1.80. The firm has a market capitalization of $158.33 million, a PE ratio of -1.11 and a beta of 1.18. The firm’s 50 day simple moving average is $1.30 and its 200 day simple moving average is $1.18.

Lucid Diagnostics (NASDAQ:LUCD) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The business had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $1.39 million. Research analysts forecast that Lucid Diagnostics will post -0.84 earnings per share for the current year.

Institutional Trading of Lucid Diagnostics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Centiva Capital LP purchased a new position in Lucid Diagnostics in the third quarter worth $25,000. Sprott Inc. purchased a new stake in Lucid Diagnostics during the third quarter valued at about $25,000. SG Americas Securities LLC purchased a new stake in Lucid Diagnostics during the third quarter valued at about $26,000. Quadrature Capital Ltd bought a new stake in Lucid Diagnostics during the second quarter worth about $29,000. Finally, Abel Hall LLC bought a new stake in Lucid Diagnostics during the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 74.01% of the company’s stock.

Key Lucid Diagnostics News

Here are the key news stories impacting Lucid Diagnostics this week:

• Positive Sentiment: Company signaled expanded U.S. Department of Veterans Affairs market access and reported 29% sequential test-volume growth while management said it is targeting Medicare and commercial payer wins — a clear commercialization catalyst if reimbursement gains follow. Lucid Diagnostics signals expanded VA market access and 29% sequential test volume growth
• Positive Sentiment: Needham & Company reaffirmed a Buy rating and set a $3.00 price target, implying substantial upside from current levels — analyst support can boost investor confidence and trading interest. Benzinga
• Positive Sentiment: Company reported Q4 operational progress: processed 3,664 EsoGuard tests, recognized $1.5M in revenue, and highlighted positive real‑world data from esophageal precancer detection — evidence that commercial adoption and clinical validation are advancing. Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Management commentary and the full earnings-call/transcript provide additional color on commercialization priorities, payer strategy and next milestones; useful for gauging timeline risk but not an immediate price driver on its own. Q4 2025 Earnings Call Transcript Earnings Transcript (Yahoo)
• Neutral Sentiment: Third‑party summaries note revenue outpaced consensus (about $1.5M) and the company increased cash to roughly $34.7M, but institutional holdings show mixed buying and large position changes — signals of both interest and repositioning by larger holders. QuiverQuant: Stock Rises on Q4 2025 Earnings
• Negative Sentiment: Profitability remains a concern: Lucid reported a $0.10 per-share loss in Q4, which was worse than one estimate and highlights ongoing operating losses and negative cash flow — key risks if revenue and reimbursement progress don’t accelerate. Zacks: Reports Q4 Loss, Beats Revenue Estimates

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.